Literature DB >> 18022850

MR pharmacokinetic modeling of the patellar cartilage differentiates normal from pathological conditions.

Roberto Sanz1, Luis Martí-Bonmatí, José Luis Rodrigo, David Moratal.   

Abstract

PURPOSE: To study the pharmacokinetic parameters derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the patellar cartilage under normal and pathological conditions.
MATERIALS AND METHODS: DCE-MRI was obtained in 22 cases. There were 17 patients with degenerative patellar conditions (eight with chondromalacia and nine with osteoarthritis) and five normal subjects. The cartilage pharmacokinetic parameters of K(trans) (vascular permeability), k(ep) (extraction ratio), upsilon(e) (extravascular extracellular space [EES] volume fraction), and upsilon(p) (intravascular space volume fraction) were extracted.
RESULTS: Statistically significant differences were observed between the different groups (normal cartilage, chondromalacia and osteoarthritis) for K(trans) and upsilon(e). K(trans) values were (mean +/- SD) 1.06 +/- 0.62, 11.97 +/- 8.91, and 21.21 +/- 16.03 mL x minute(-1) x 100 mL(-1) (P < 0.02), respectively; and upsilon(e) values were 0.71 +/- 0.69, 3.59 +/- 2.21, and 10.51 +/- 8.20% (P < 0.002). Reproducibility of the pharmacokinetic calculations was assessed with a second set of analyses of 10 random cases one week after the first analysis, showing a test-retest root mean square (RMS) coefficient of variation of 9.78% for K(trans) and 14.72% for upsilon(e).
CONCLUSION: The vascular permeability and EES fraction of cartilage increases with the severity of the degeneration. Pharmacokinetic models allow to study the vascular properties of the cartilage and may have applications as a surrogate index in longitudinal studies to quantify the evolution of drug trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18022850     DOI: 10.1002/jmri.21233

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

1.  Intra-individual assessment of inflammatory severity and cartilage composition of finger joints in rheumatoid arthritis.

Authors:  C Schleich; A Müller-Lutz; P Sewerin; B Ostendorf; C Buchbender; M Schneider; G Antoch; F Miese
Journal:  Skeletal Radiol       Date:  2014-11-01       Impact factor: 2.199

2.  Cartilage quality in rheumatoid arthritis: comparison of T2* mapping, native T1 mapping, dGEMRIC, ΔR1 and value of pre-contrast imaging.

Authors:  Christian Buchbender; Axel Scherer; Patric Kröpil; Birthe Körbl; Michael Quentin; Dorothea Ch Reichelt; Rotem S Lanzman; Christian Mathys; Dirk Blondin; Bernd Bittersohl; Christoph Zilkens; Matthias Hofer; Hans-Jörg Wittsack; Matthias Schneider; Gerald Antoch; Benedikt Ostendorf; Falk Miese
Journal:  Skeletal Radiol       Date:  2011-09-20       Impact factor: 2.199

Review 3.  Osteoarthritis revisited---again!

Authors:  Iain Watt
Journal:  Skeletal Radiol       Date:  2009-05       Impact factor: 2.199

Review 4.  Responsiveness and reliability of MRI in knee osteoarthritis: a meta-analysis of published evidence.

Authors:  D J Hunter; W Zhang; P G Conaghan; K Hirko; L Menashe; W M Reichmann; E Losina
Journal:  Osteoarthritis Cartilage       Date:  2011-03-23       Impact factor: 6.576

5.  Glucosamine sulfate effect on the degenerated patellar cartilage: preliminary findings by pharmacokinetic magnetic resonance modeling.

Authors:  Luis Martí-Bonmatí; Roberto Sanz-Requena; José Luis Rodrigo; Angel Alberich-Bayarri; José Miguel Carot
Journal:  Eur Radiol       Date:  2009-02-13       Impact factor: 5.315

6.  Proteoglycan loss in the articular cartilage is associated with severity of joint inflammation in psoriatic arthritis-a compositional magnetic resonance imaging study.

Authors:  Daniel B Abrar; Christoph Schleich; Sven Nebelung; Miriam Frenken; Tim Ullrich; Karl Ludger Radke; Gerald Antoch; Stefan Vordenbäumen; Ralph Brinks; Matthias Schneider; Benedikt Ostendorf; Philipp Sewerin
Journal:  Arthritis Res Ther       Date:  2020-05-29       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.